Dr. Ron Babecoff co-founded BiondVax (www.biondvax.com) in 2003, and has led the company as its President and CEO since its inception. He has guided the company through 5 successful clinical trials (Phase 1/2 and 2), and two ongoing Phase 2 trials in collaboration with the EU and the US NIH towards the Phase 3 for its Universal Flu Vaccine. BiondVax Pharmaceuticals Ltd. is now a public biotech company listed on the NASDAQ: BVXV and TASE: BVXV.
Prior to founding BiondVax, Dr. Babecoff worked for 10 years in marketing and business development in the pharmaceutical industry. As Marketing Manager at Omrix Biopharmaceuticals Ltd., he was responsible for marketing, sales training, public relations, and new product development. His professional experience ranges from identifying West Nile Fever treatments, building cooperation with the NIH, to forming alliances with leading international pharmaceutical companies.
Dr. Babecoff holds a D.V.M. degree from the University of Liège (ULg), Belgium and a Master of Entrepreneurship and Innovation (MEI) from the Swinburne University of Technology of Melbourne, Australia.